"Drugs: the industry counts the places at risk"
(la Repubblica Affari & Finanza: page 12 – 24 November 2008)
Over 4,000 pharmaceutical industry jobs have been lost worldwide in the last 2 years. To these could be added another 5,000 redundancies by 2010, in total about 15% of the workforce. The situation is not rosy in Italy either where despite this, until last year the numbers were positive: production +1.1%, export of medicines +1.6%. In addition, investments in research have increased by 32.5% from 2002 to date and there are 1,000 more researchers.
http://www.aboutpharma.it/notizia.asp?id=18330
Philips lays off 1,600 people in the medical sector(Les Echos online – November 24, 2008)
Philips has decided to cut, worldwide, the 5% of the 32,000 employees in the medical sector, around 1,600 people. Most of the layoffs will concern the US.
http://www.aboutpharma.it/notizia.asp?id=18326
NicOx: Positive results for Naproxcinod
(Les Echos online – November 24, 2008)
NicOx said that the results of the third series of clinical studies on the anti-inflammatory Naproxicinod conducted on patients with hip osteoarthritis are positive. The data indicate that gastrointestinal and blood pressure side effects are similar to those observed in patients treated with placebo. The company will submit the dossier to the FDA in mid-2009.
http://www.aboutpharma.it/notizia.asp?id=18324
"Sanofi-Aventis, like the change at the top"
(la Repubblica Affari & Finanza: page 23 – 24 November 2008)
Analysts approve the appointment of Chris Viehbacher as CEO of Sanofi-Aventis. Merill Lynch confirms the purchase judgment on the stock and the price of 53 euros. The investment bank underlines the solidity of the company, confirmed by a dividend policy that rewards shareholders. Judgment "buy" also from Dresdner Kleinwort.
http://www.aboutpharma.it/notizia.asp?id=18323
Emea: new drug from Recordati
(Finance & Markets: page 2 – 22 November 2008)
Recordati has submitted to Emea the request for marketing authorization for a new silodosin-based drug, indicated for the treatment of the signs and symptoms of benign prostatic hyperplasia. The company expects to obtain approval in the first half of 2010. The molecule is from the Japanese Kissei Pharmaceutical and enjoys patent protection until 2018 in Europe and exclusivity in the use of clinical data until 2010. Recordati has been licensed for the whole of Europe, as well as 18 countries in the Middle East and Africa. In Piazza Affari, the stock gained 1.08%.
http://www.aboutpharma.it/notizia.asp?id=18325
Eli Lilly successfully completes acquisition of ImClone
(Les Echos online – November 21, 2008; Les Echos online – November 24, 2008)
Eli Lilly has successfully completed the takeover bid on the biotech ImClone, of which it has already acquired 95.5% of the capital at 70 dollars per share.
http://www.aboutpharma.it/notizia.asp?id=18329
Agreement between GSK and the Chinese Neptunus(Les Echos online – November 21, 2008)
GlaxoSmithKline has signed an exclusive cooperation agreement with the company
